Event

Our moderator and expert-panel will lead an interactive discussion of three asthma patient case studies highlighting the importance of Type 2 inflammation in asthma control, severity and lung function. Using an ARS response system, attendees will help evaluate the significance of patient clinical features and Type 2 biomarkers. Discussion throughout will focus on how clinical features, biomarkers and lung function results (eg. FEV1) together may inform patient severity, control and exacerbation risk. We will also discuss how indicators of irreversible lung function decline, as well as uncontrolled Type 2 inflammation, could reflect airway structural changes.